Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension

Hypertension

Volumn 40, Issue 4, 2002, Pages 528-534

  Maniu, Calin V ^a   Meyer, Donna M ^a   Redfield, Margaret M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Angiotensin; Drug therapy; Hemodynamics; Hypertension, experimental; Natriuretic peptides

Indexed keywords

ADRENOMEDULLIN; ANGIOTENSIN ANTAGONIST; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; NATRIURETIC FACTOR; OMAPATRILAT; VASOPEPTIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DOG; DRUG EFFECT; DRUG INFUSION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE PRESSURE; HEMODYNAMIC MONITORING; HUMAN; HYPERTENSION; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL;

ADRENOMEDULLIN; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ATRIAL NATRIURETIC FACTOR; DOGS; FOSINOPRIL; HEMODYNAMIC PROCESSES; HYPERTENSION; KINETICS; MALE; NEPRILYSIN; PEPTIDES; PROTEASE INHIBITORS; PYRIDINES; THIAZEPINES; VASOCONSTRICTOR AGENTS;

EID: 0036792776     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000033223.17484.B1     Document Type: Article

References (30)

1. Robl JA, Sun CQ, Stevenson J, Ryono DE, Simpkins LM, Cimarusti MP, Dejneka T, Slusarchyk WA, Chao S, Stratton L, Misra RN, Bednarz MS, Asaad MM, Cheung HS, Abboa-Offei BE, Smith PL, Mathers PD, Fox M, Schaeffer TR, Seymour AA, Trippodo NC. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem. 1997;40:1570-1577.
2. Corti R, Burnett JC Jr, Rouleau JL, Ruschitzka F, Luscher TF. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation. 2001;104:1856-1862.
3. Blais C Jr, Fortin D, Rouleau JL, Molinaro G, Adam A. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts. J Pharmacol Exp Ther. 2000;295:621-626.
4. Lisy O, Jougasaki M, Schirger JA, Chen HH, Barclay PT, Burnett JC Jr. Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. Am J Physiol. 1998;275:F410-F414.
5. Weber MA. Vasopeptidase inhibitors. Lancet. 2001;358:1525-1532.
6. Page IH. A method for producing hypertension by cellophane. Science. 1939:273-274.
7. Hart CY, Meyer DM, Tazelaar HD, Grande JP, Burnett JC Jr, Housmans PR, Redfield MM. Load versus humoral activation in the genesis of early hypertensive heart disease. Circulation. 2001;104:215-220.
8. Lainchhury JG, Burnett JC Jr, Meyer D, Redfield MM. Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs. Am J Physiol Heart Circ Physiol. 2000;278:H33-H40.
9. Lainchhury JG, Meyer DM, Jougasaki M, Burnett JC Jr, Redfield MM. Effects of adrenomedullin on load and myocardial performance in normal and heart-failure dogs. Am J Physiol Heart Circ Physiol. 2000;279:H1000-H1006.
10. Thomas CV, McDaniel GM, Holzgrefe HH, Mukherjee R, Hird RB, Walker JD, Hebbar L, Powell JR, Spinale FG. Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs. J Cardiovasc Pharmacol. 1998;32:902-912.
11. Kohlstaedt KG, Page IH, Helmer OM. The activation of renin by blood. Am Heart J. 1939:92-99.
12. Kitamura K, Eto T. Adrenomedullin-physiological regulator of the cardiovascular system or biochemical curiosity? Curr Opin Nephrol Hypertens. 1997;6:80-87.
13. Burrell LM, Droogh J, Man in't Veld O, Rockell MD, Farina NK, Johnston CI. Antihypertensive and antihypertrophic effects of omapatrilat in SHR. Am J Hypertens. 2000;13:1110-1116.
14. Intengan HD, Schiffrin EL. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats. Hypertension. 2000;35:1221-1225.
15. Quaschning T, d'Uscio LV, Shaw S, Luscher TF. Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension. Hypertension. 2001;37:1108-1113.
16. Trippodo NC, Rohl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens. 1998;11:363-372.
17. Tikkanen T, Tikkanen I, Rockell MD, Allen TJ, Johnston CI, Cooper ME, Burrell LM. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. Hypertension. 1998;32:778-785.
18. Campese VM, Lasseter KC, Ferrario CM, Smith WB, Ruddy MC, Grim CE, Smith RD, Vargas R, Hahashy MF, Vesterqvist O, Delaney CL, Liao WC. Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension. 2001;38:1342-1348.
19. Campbell WG Jr, Donohue JA, Duket LH. Serum angiotensin converting enzyme activity and the capacity to develop hypertension-associated arterial disease: studies during the induction phase of one-kidney perinephritis hypertension in rabbits. Am J Pathol. 1978;93:383-404.
20. Johnson JA, Stubbs D, Keitzer WF. Role of the renin-angiotensin system in dogs with perinephritis hypertension. Proc Soc Exp Biol Med. 1976;152:560-564.
21. Cataliotti A, Boerrigter G, Chen HH, Jougasaki M, Costello LC, Tsuruda T, Lee SC, Malatino LS, Burnett JC Jr. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure. Circulation. 2002;105:639-644.
22. Cohn JN. Relationship of plasma volume changes to resistance and capacitance vessel effects of sympathomimetic amines and angiotensin in man. Clin Sci. 1966;30:267-278.
23. Fitzpatrick MA, Julius S. Hemodynamic effects of angiotensin-converting enzyme inhibitors in essential hypertension: a review. J Car. diovasc Pharmacol. 1985;7:S35-S39.
24. Espiner EA. Physiology of natriuretic peptides. J Intern Med. 1994;235:527-541.
25. Yoshimura M, Yasue H, Morita E, Sakaino N, Jougasaki M, Kurose M, Mukoyama M, Saito Y, Nakao K, Imura H. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1991;84:1581-158.
26. Chen HH, Lainchbury JG, Matsuda Y, Harty GJ, Burnett JC Jr. Endogenous natriuretic peptides participate in renal and humoral actions of acute vasopeptidase inhibition in experimental mild heart failure. Hypertension. 2001;38:187-191.
27. Kohno M, Hanehira T, Kano H, Horio T, Yokokawa K, Ikeda M, Minami M, Yasunari K, Yoshikawa J. Plasma adrenomedullin concentrations in essential hypertension. Hypertension. 1996;27:102-107.
28. Kato J, Kitamura K, Matsui E, Tanaka M, Ishizaka Y, Kita T, Kangawa K, Eto T. Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. Hypertens Res. 1999;22:61-65.
29. Troughton RW, Lewis LK, Yandle TG, Richards AM, Nicholls MG. Hemodynamic, hormone, and urinary effects of adrenomedullin infusion in essential hypertension. Hypertension. 2000;36:588-593.
30. Xu J, Carretero OA, Liu YH, Shesely EG, Yang F, Yang XP. Role of kinins and natriuretic peptides in the cardioprotective effect of omapatrilat in mice with MI. Circulation. 2001;104(suppl II):II-280-II-281. Abstract.